HC Wainwright Has Pessimistic Outlook of NERV Q3 Earnings

Minerva Neurosciences, Inc (NASDAQ:NERV) – HC Wainwright cut their Q3 2026 earnings per share estimates for Minerva Neurosciences in a report issued on Monday, August 10th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings of ($0.14) per share for the quarter, down from their prior forecast of ($0.01). The consensus estimate for Minerva Neurosciences’ current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Minerva Neurosciences’ Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.50) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.11) EPS, FY2027 earnings at ($0.42) EPS, FY2028 earnings at ($0.15) EPS, FY2029 earnings at $0.64 EPS and FY2030 earnings at $1.67 EPS.

NERV has been the subject of a number of other research reports. Citizens Jmp began coverage on Minerva Neurosciences in a research report on Wednesday, April 15th. They set a “market outperform” rating and a $14.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Minerva Neurosciences in a report on Wednesday, June 24th. Finally, Wall Street Zen raised shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a research report on Saturday. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Minerva Neurosciences presently has an average rating of “Hold” and a consensus target price of $10.50.

Minerva Neurosciences Stock Performance

Shares of Minerva Neurosciences stock opened at $4.32 on Wednesday. The business’s 50 day simple moving average is $4.50 and its 200 day simple moving average is $5.43. Minerva Neurosciences has a 52-week low of $1.76 and a 52-week high of $12.46. The firm has a market cap of $206.28 million, a PE ratio of -0.15 and a beta of -0.10.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Friday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.05.

Hedge Funds Weigh In On Minerva Neurosciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC bought a new position in shares of Minerva Neurosciences in the fourth quarter valued at about $36,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Minerva Neurosciences during the 1st quarter worth about $62,000. State Street Corp boosted its holdings in shares of Minerva Neurosciences by 45.4% during the 4th quarter. State Street Corp now owns 24,019 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 7,500 shares during the period. Cannon Global Investment Management LLC acquired a new position in Minerva Neurosciences in the 1st quarter valued at about $107,000. Finally, Bank of America Corp DE grew its stake in Minerva Neurosciences by 78,272.5% in the 1st quarter. Bank of America Corp DE now owns 39,970 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 39,919 shares during the last quarter. 34.56% of the stock is currently owned by institutional investors and hedge funds.

Minerva Neurosciences News Roundup

Here are the key news stories impacting Minerva Neurosciences this week:

• Positive Sentiment: HC Wainwright still projects a potential long-term earnings recovery, forecasting positive EPS of $0.64 in fiscal 2029 and $1.67 in fiscal 2030. These estimates suggest analysts see possible upside if Minerva’s pipeline and commercial plans succeed.
• Neutral Sentiment: The latest short-interest report showed no reported shares sold short and a zero-day days-to-cover ratio. However, the figures appear unreliable because both the current and prior short-interest totals were reported as zero, limiting their usefulness as a trading signal.
• Negative Sentiment: HC Wainwright cut its fiscal 2026 EPS forecast to a loss of $0.50 from a loss of $0.20, while reducing quarterly estimates for the third and fourth quarters of 2026 to losses of $0.14 and $0.09 per share, respectively. The firm also lowered its second- and third-quarter 2027 estimates to losses of $0.11 per share.
• Negative Sentiment: The most significant revision was to fiscal 2027, with expected EPS reduced to a loss of $0.42 from previously projected earnings of $4.82. Fourth-quarter 2027 EPS was also cut to a loss of $0.11 from an earlier forecast of $1.95. The new estimates are well below the company’s current full-year consensus forecast of a $0.20 loss per share.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.